Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Aug 24, 2026
Why Is OmniAb (OABI) Stock Up +0.70% Today?

Why Is OmniAb (OABI) Stock Up +0.70% Today?

Key Takeaways

  • OABI shares closed at $4.33, up 0.70% ($0.03), extending a powerful multi-week advance.
  • The gain capped a week in which the stock climbed roughly 28% and came within about 6% of its 52-week high of $4.59.
  • Momentum traces back to a blowout Q2 report (revenue up 244% year over year) and a new Eli Lilly collaboration worth up to $370 million in milestones.
  • Management raised guidance twice, lifting 2026 revenue to $32–36 million and year-end cash to $49–53 million.
  • Volume ran well above average, while technical indicators signaled an extended, overbought setup.
  • Traders are watching the October 6 Investor & Analyst Day and the Q3 earnings report expected in early November.

Opening Summary

OmniAb, Inc. (OABI), an Emeryville, California-based biotechnology company that licenses antibody-discovery technology to pharmaceutical and biotech partners, closed the latest session at $4.33, up 0.70% from the prior close of $4.30. The move confirmed the stock's upward trajectory, which has now carried shares roughly 105% higher over the past month and more than 134% higher year to date. Markets attributed the continued strength to a combination of a strong second-quarter earnings beat, an upgraded financial outlook, and a high-profile partnership with Eli Lilly announced earlier in the month.

Earnings Beat and Raised Guidance Fuel Momentum

The foundation of the rally was laid on August 6, when OmniAb reported second-quarter results that far exceeded Wall Street expectations. Total revenue reached $13.4 million, up 244% from $3.9 million a year earlier, while the net loss narrowed to $5.9 million, or $0.05 per share, from $15.9 million a year ago. The company beat consensus estimates of a $0.12-per-share loss and roughly $4.7 million in revenue, driven largely by milestone payments as partner programs advanced in clinical development.

Management followed the report by raising full-year 2026 revenue guidance to a range of $32 million to $36 million, and later lifted its year-end cash outlook to $49 million to $53 million from a prior $37 million to $41 million. The company ended the second quarter with 110 active partners, 425 active programs, 34 active clinical programs, and more than $3 billion in contracted potential milestone payments, reinforcing the long-term licensing story.

Eli Lilly Collaboration Anchors the Rally

The sharpest single catalyst arrived on August 17, when OmniAb announced a global collaboration and license agreement with Eli Lilly (LLY) for a new ion channel discovery program. Under the terms, Lilly will use OmniAb's ion channel discovery and screening capabilities, with OmniAb eligible for up to $370 million in research, development, and commercial milestone payments, plus tiered royalties on global net sales. The undisclosed upfront payment and expanded cash outlook reduced near-term dilution risk and gave management additional runway, factors that fueled a double-digit premarket surge that has since consolidated into a steady grind higher.

Analyst Support and Technical Momentum

Adding to the bullish backdrop, HC Wainwright reiterated a Buy rating with an $11 price target following the earnings and partnership news. On a technical basis, OABI trades well above its 50-day and 200-day moving averages, and its relative strength reading has been among the highest in the market. The stock broke decisively above its prior 52-week high near $3.63, which now serves as a key support level, though momentum indicators such as the RSI sit near overbought territory, signaling the possibility of profit-taking or consolidation.

Market Context and Trading Activity

The latest session was choppy rather than one-directional. Shares opened near $4.31, climbed to an intraday high of $4.535, pulled back to $4.14, and recovered to close at $4.33. Volume of roughly 1.85 million shares ran well above the stock's average of about one million, indicating sustained participation rather than a one-off spike. The advance has been largely company-specific: broader equity indices moved modestly, and the move reflects OmniAb-specific catalysts rather than broad sector sympathy, even as the biotech and life-sciences-tools complex has generally supported growth-stage names.

What Comes Next for OABI

Investors will look next to OmniAb's Investor & Analyst Day on October 6 and its third-quarter earnings report, expected in early November. Key drivers include continued advancement of partner programs, additional clinical entrants, and any further progress on the xPloration screening platform. Risks remain material: milestone revenue is inherently lumpy, the company is still unprofitable, and shares are technically extended after a triple-digit run. The stock's heavy reliance on partner decisions and clinical timelines means quarterly results can vary significantly, even as the contracted milestone base provides longer-term visibility.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of automated bots covering thousands of tickers, with strategies that differ by approach, timeframe, performance metrics, and traded symbols. Only those demonstrating standout results are featured in this section. Explore the Trending AI Robots to see which strategies are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OABI

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


OABI in -6.84% downward trend, declining for three consecutive days on September 10, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OABI declined for three days, in 205 of 245 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for OABI moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 26 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OABI as a result. In 64 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for OABI turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 34 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 63 cases where OABI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where OABI advanced for three days, in 143 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 79 of 177 cases where OABI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.497) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (14.124) is also within normal values, averaging (437.043).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OABI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OABI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 7%. NRSN experienced the highest price growth at 1,794%, while LGVN experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 108%. For the same stocks of the Industry, the average monthly volume growth was 48% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
OABI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
5980 Horton Street
Phone
+1 510 250-7800
Employees
89
Web
https://www.omniab.com
Interact to see
Advertisement
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.
Why Is OmniAb (OABI) Stock Up +0.70% Today?